Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting
- PMID: 6979415
- PMCID: PMC2536029
Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting
Abstract
For the determination of the plasma concentration profiles of pyrimethamine and sulfadoxine after the administration of 1 tablet of Fansidar, highly specific analytical methods are needed as the pyrimethamine concentration is low (0.2 - 0.02 mg/litre) and the concentration ratio of the two components in the plasma is high (> 1: 500). The microbiological method described in this paper fulfils these requirements for high specificity and sensitivity (the sensitivity limit for sulfadoxine is 1 mg/litre and for pyrimethamine is 0.013 mg/litre).Pharmacokinetic data were evaluated for 14 volunteers after administration of 1 tablet of Fansidar, and a computer simulation of multiple dosing (1 tablet per week) was performed.
Similar articles
-
Pharmacokinetics of sulfadoxine and pyrimethamine after Fansidar administration in man.Chemotherapy. 1987;33(4):229-33. doi: 10.1159/000238499. Chemotherapy. 1987. PMID: 3608621
-
Plasma concentrations of sulfadoxine in healthy and malaria infected Thai subjects.Acta Trop. 1988 Sep;45(3):217-24. Acta Trop. 1988. PMID: 2903623
-
Absence of pharmacokinetic interaction between Fansidar and mefloquine.Trans R Soc Trop Med Hyg. 1986;80(6):1001-2. doi: 10.1016/0035-9203(86)90297-x. Trans R Soc Trop Med Hyg. 1986. PMID: 3496691 No abstract available.
-
Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects.Chemotherapy. 1987;33(1):1-8. doi: 10.1159/000238468. Chemotherapy. 1987. PMID: 3493885
-
Evaluation of an in vitro test method for the assessment of sensitivity of Plasmodium falciparum to pyrimethamine and sulfadoxine.Bull World Health Organ. 1987;65(3):345-52. Bull World Health Organ. 1987. PMID: 3311437 Free PMC article.
Cited by
-
Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.Antimicrob Agents Chemother. 2004 Oct;48(10):3794-800. doi: 10.1128/AAC.48.10.3794-3800.2004. Antimicrob Agents Chemother. 2004. PMID: 15388436 Free PMC article. Clinical Trial.
-
A pivot mutation impedes reverse evolution across an adaptive landscape for drug resistance in Plasmodium vivax.Malar J. 2016 Jan 25;15:40. doi: 10.1186/s12936-016-1090-3. Malar J. 2016. PMID: 26809718 Free PMC article.
-
Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges.Matern Child Health J. 2011 May;15(4):542-52. doi: 10.1007/s10995-010-0608-5. Matern Child Health J. 2011. PMID: 20425139
-
Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.Antimicrob Agents Chemother. 2011 Apr;55(4):1693-700. doi: 10.1128/AAC.01075-10. Epub 2011 Jan 31. Antimicrob Agents Chemother. 2011. PMID: 21282434 Free PMC article. Clinical Trial.
-
Sulfadoxine-pyrimethamine resistant malaria from west or central Africa.Br Med J (Clin Res Ed). 1988 Feb 6;296(6619):433. doi: 10.1136/bmj.296.6619.433-a. Br Med J (Clin Res Ed). 1988. PMID: 3125942 Free PMC article. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources